Autologous Natural Killer T Cells Infusion for the Treatment of Cancer
The purpose of this study is to assess the safety and effectiveness of natural killer T (NKT) cell-based autologous adoptive immunotherapy in subjects with metastatic, treatment-refractory breast cancer, glioma, hepatocellular carcinoma, squamous cell lung cancer, pancreatic cancer, colon cancer or prostate cancer.
Breast Cancer|Glioma|Hepatocellular Cancer|Squamous Cell Lung Cancer|Pancreatic Cancer|Colon Cancer|Prostate Cancer
BIOLOGICAL: NKT cells
Occurrence of study related adverse events, defined as \>= Grade 3 signs/symptoms, laboratory toxicities, and clinical events) that are possibly, likely, or definitely related to study treatment, Until week 24
Anti-tumor responses to NKT cells infusions, at least once within 30 days afther completing four-cycle treatment
A randomized controlled trial on the efficacy and safety of autologous natural killer T (NKT) cells infusion treatment in advanced cancer.